Roivant Posts $31M LISRAYA Launch, IMVT-1402 Hits RA Endpoint

Roivant Sciences Ltd. (Nasdaq: ROIV) reported second-quarter fiscal 2026 results on November 9, 2026, disclosing $31.0 million in net product revenue from LISRAYA (brepocitinib) in the drug's first five weeks of U.S. commercial availability following August 2026 FDA approval. The company also said IMVT-1402 600 mg met the primary ACR20 endpoint at Week 28 in a potentially registrational difficult-to-treat rheumatoid arthritis trial, 92.5% versus 75.6% for placebo (p=0.0139). Consolidated cash, cash equivalents and marketable securities stood at $4.2 billion as of September 30, 2026.

Context — why this quarter matters for Roivant

The quarter marks Roivant's transition from a clinical-stage holding company to one with a marketed product. The report gives the prior-year comparison directly: product revenue was zero in the three months ended September 30, 2025, so the $31.0 million figure is the first commercial contribution in the company's history.

The IMVT-1402 result arrives after an open-label lead-in in Period 1, where 170 participants received the 600 mg dose for 16 weeks. Only patients meeting ACR20 criteria at Weeks 14 and 16 advanced to the randomized withdrawal Period 2, which is why the efficacy analysis covered 117 participants rather than the full enrolled population.

That design matters for interpretation. A randomized withdrawal trial enriches for responders before randomization, so the placebo arm's 75.6% maintenance rate reflects patients who already responded once. The 600 mg dose still separated from placebo; the 300 mg dose did not, at 75.0% and p=0.9426.

The company said it plans FDA discussions later this year to determine the path forward for the registrational program in D2T RA. Roivant also said it is unlikely to advance IMVT-1402 further in Sjögren's disease beyond the ongoing, fully enrolled Phase 2 trial, citing the evolving SjD landscape and recent field data.

Separately, brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis, with a supplemental New Drug Application expected in the first half of calendar 2027.

Data — what the numbers show

Product revenue, net of $31.0 million compares against zero in the prior-year quarter. R&D expenses fell $18.8 million to $145.7 million from $164.6 million, driven by a $7.4 million drop in personnel-related expense, $6.4 million in program-specific costs and $3.0 million in share-based compensation.

Within program costs, anti-FcRn spending fell $18.3 million, reflecting lower spend on the IMVT-1402 cutaneous lupus erythematosus study discontinued in September 2026, the wind-down of batoclimab trials and contract manufacturing timing. Mosliciguat costs rose $11.6 million as that program advanced.

SG&A rose $11.0 million to $154.1 million, mostly from the LISRAYA commercial launch, partly offset by an $11.2 million prior-year charge for one-time cash retention awards.

Metric	Q2 FY2026	Q2 FY2025
Product revenue, net	$31.0M	$0
R&D expense	$145.7M	$164.6M
SG&A expense	$154.1M	$143.1M
Loss from continuing ops	$153.0M	$166.0M
Net loss attributable to Roivant	$191.6M	$113.5M

Net loss attributable to Roivant widened to $191.6 million from $113.5 million, including $95.9 million of distributions on Genevant Sciences Ltd. restricted stock units and options that participated in Moderna settlement proceeds through dividend-equivalent rights. Those distributions added $0.13 to both basic and diluted loss per share. Adjusted loss from continuing operations narrowed to $133.4 million from $187.8 million.

Analysis — what it means for biotech and Immunovant holders

The D2T RA readout is the quarter's most consequential item for Immunovant, Roivant's anti-FcRn subsidiary. The 300 mg miss narrows the commercial dose to 600 mg and gives the FDA a clean efficacy signal to weigh. Secondary endpoints on CDAI and SDAI numerically favored 600 mg but did not reach significance, at p=0.1096 and p=0.1299, and the trial was not powered for the ACR50 and ACR70 exploratory measures.

That is the counter-argument. A registrational package built on a single significant primary endpoint, in an enriched population, with non-significant key secondaries, leaves room for the agency to request an additional trial. The company's own language, framing the meeting as determining the path forward, signals that outcome is open.

For the broader immunology space, a validated 600 mg subcutaneous anti-FcRn asset in refractory RA would compete in a patient pool that has failed multiple advanced therapies, a segment where existing options are limited. The SjD pullback removes one indication from the pipeline narrative without touching the Graves' disease, myasthenia gravis and CIDP timelines, which the company said remain on track.

The $4.2 billion cash position, which the company said supports runway into profitability, is the balance-sheet fact that underwrites the multi-year development plan. Roivant repurchased 2.1 million shares for roughly $72.5 million during the quarter.

Outlook — what to watch next

The FDA meeting on the D2T RA registrational path is the near-term catalyst, with the company guiding to discussions later this year. The brepocitinib sNDA filing for NIU is expected in the first half of calendar 2027, and Phase 3 cutaneous sarcoidosis topline is guided to calendar 2028.

Immunovant expects topline data across potentially registrational IMVT-1402 trials in Graves' disease and myasthenia gravis in calendar 2027, with CIDP data in calendar 2028. The Phase 3 PHrontier study of mosliciguat and the Phase 2 PHactor combination study with inhaled treprostinil are both enrolling.

On the litigation side, an additional $1.3 billion from the Moderna settlement is contingent on a resolution of Moderna's Section 1498 appeal favorable to Genevant and Arbutus. Oral arguments took place November 5, 2026. Roivant will host an Investor Day in New York City and virtually on December 9, 2026.

The report did not disclose pricing terms for LISRAYA or gross-to-net dynamics behind the $31.0 million net figure.

Frequently Asked Questions

What does the IMVT-1402 600 mg result mean for retail investors?

It means Immunovant's lead asset cleared a clinical hurdle but not the regulatory one. The 92.5% versus 75.6% ACR20 separation at Week 28 was statistically significant, yet the 300 mg dose failed and key secondary endpoints missed significance. The company must still negotiate the registrational design with the FDA, so the commercial path is unresolved even though the efficacy signal is positive.

Why did Roivant's net loss widen while adjusted loss narrowed?

The gap is Genevant. Net loss attributable to Roivant included $95.9 million of distributions on Genevant restricted stock units and options tied to Moderna settlement proceeds, adding $0.13 per share to the loss. Excluding share-based compensation, depreciation, investment fair-value changes and that item, adjusted loss from continuing operations narrowed to $133.4 million from $187.8 million a year earlier.

How much cash does Roivant have and how long does it last?

Roivant reported $4.2 billion in consolidated cash, cash equivalents and marketable securities as of September 30, 2026, up from the $1.4 billion cash and $2.9 billion marketable securities reported at March 31, 2026, with the increase reflecting the Moderna payment received in July. The company said the position supports cash runway into profitability, without specifying a date.

Bottom Line

Roivant's first product revenue and a positive RA endpoint give it two independent value drivers, but the FDA meeting will decide how far the second one travels.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.